<DOC>
	<DOCNO>NCT02541370</DOCNO>
	<brief_summary>RATIONALE : Placing tumor antigen chimeric receptor create laboratory patient autologous donor-derived T cell may make body build immune response kill cancer cell . PURPOSE : This clinical trial study genetically engineer lymphocyte therapy treat patient Relapsed and/or Chemotherapy Refractory Advanced Malignancies .</brief_summary>
	<brief_title>Treatment Relapsed and/or Chemotherapy Refractory Advanced Malignancies CART133</brief_title>
	<detailed_description>I . Determine safety feasibility chimeric antigen receptor T cell transduce anti-CD133 ( cluster differentiation antigen 133 ) vector ( refer CART-133 cell ) . II . Determine duration vivo survival CART-133 cell . RT-PCR ( reverse transcription polymerase chain reaction ) analysis whole blood use detect quantify survival CART-133 TCR ( T-cell receptor ) zeta : CD137 TCR zeta cell time . SECONDARY OBJECTIVES : I . For patient detectable disease , measure anti-tumor response due CART-133 cell infusion . II . To determine CD137 transgene superior TCR zeta transgene measure relative engraftment level CART-133 TCR zeta : CD137 TCR zeta cell time . III . Estimate relative traffic CART-133 cell tumor bone marrow lymph node . IV . For patient store accessible tumor cell determine tumor cell kill CART-133 cell vitro . V. Determine cellular humoral host immunity develop murine anti-CD133 , assess correlation loss detectable CART-133 ( loss engraftment ) . VI . Determine relative subset CART-133 T cell ( Tcm , Tem , Treg ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>1 . Chemotherapy refractory relapse CD133positive liver cancer , pancreatic cancer , brain tumor , breast cancer , ovarian tumor , colorectal cancer acute leukemia . 2 . Patients must 18 year age old . 3 . Patients must ECOG ( Eastern Cooperative Oncology Group ) performance status 02 . 4 . Patients must evidence adequate bone marrow reserve , hepatic renal function evidence follow laboratory parameter : Absolute neutrophil count great 1500/mm3 . Platelet count great 100,000/mm3 . Hemoglobin great 10g/dl ( patient may receive transfusion meet parameter ) . Total bilirubin &lt; 1.5 time upper limit normal . Serum creatinine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73m . 5 . Seronegative HIV antibody . 6 . Seronegative active hepatitis B , seronegative hepatitis C antibody . 7 . Patients must willing practice birth control four month follow treatment . NOTE : woman childbearing age must evidence negative pregnancy test . 8 . Patients must willing sign inform consent . 1 . Patients life expectancy le 12 month exclude . 2 . Patients uncontrolled hypertension ( &gt; 160/95 ) , unstable coronary disease evidence uncontrolled arrhythmia , unstable angina , decompensated congestive heart failure ( &gt; New York Heart Association Class II ) , myocardial infarction within 6 month study exclude . 3 . Patients follow pulmonary function abnormality exclude : FEV ( forced expiratory volume ) , &lt; 30 % predict ; DLCO ( diffuse capacity lung carbon monoxide ) &lt; 30 % predict ( postbronchodilator ) ; Oxygen Saturation less 90 % room air . 4 . Patients severe liver kidney dysfunction consciousness disorder exclude . 5 . Pregnant and/or lactate woman exclude . 6 . Patients active infection , include HIV , exclude , due unknown effect vaccine lymphoid precursor . 7 . Patients type primary immunodeficiency exclude study . 8 . Patients require corticosteroid ( inhale ) exclude . 9 . Patients history T cell tumor exclude . 10 . Patients participate participated clinical trial late 30 day exclude . 11 . Patients relapse acute leukemia allogeneic stem cell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>